MOTS-c(human) acetate

Name: MOTS-c(human) acetate
Brand: MedChemExpress
SKU: HY-P2048A
Rating: 4.5 (1 reviews)

Cat. No.: HY-P2048A Purity: 98.97%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

MOTS-c (human) acetate is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) acetate inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) acetate has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

MOTS-c(human) acetate Chemical Structure

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of MOTS-c(human) acetate:

MOTS-c (human) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All AMPK Isoform Specific Products:

View All Isoforms

NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

View All GLUT Isoform Specific Products:

View All Isoforms

GLUT1 GLUT2 GLUT3 GLUT4

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

AMPK

GLUT4

AICAR

In Vitro

Recent advances in high-resolution sequencing have led to the discovery of unique peptides derived from the mitochondrial genome. Eight peptides have been identified: humanin, the mitochondrial open reading frame of 12S tRNA-c (MOTS-c), and six small peptides (humanin-like peptides (SHLP1-6)). All of these peptides are released from mitochondria into the cytoplasm and are associated with extended lifespan and cell viability, reduced apoptosis, and other beneficial functions^[1].
MOTS-c (human) acetate (10 μM; 24-72 h) activates AMPK (Thr172 phosphorylation) and the expression of downstream antioxidant proteins Nrf2 and Keap1, and inhibits the phosphorylation of MAPKs (ERK, JNK, P38) in HEK293 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	HEK293 cells
Concentration:	10 μM
Incubation Time:	24-72 h
Result:	Significantly increased phosphorylation of AMPK at Thr172 and protein levels of Nrf2 and Keap1, while reducing phosphorylation of ERK, JNK, and P38. Resulted activation of AMPK by densitometric quantification, with a 2-fold increase in p-AMPK/AMPK ratio compared to control. Attenuated these effects by co-treatment with the AMPK inhibitor.

In Vivo

MOTS-c (human) (25-50 mg/kg; ip; once daily; 21 days) acetate can reduce neurological deficits and inhibit the HMGB1/TLR4/NF-κB inflammatory pathway in brain tissue in a traumatic brain injury model in male C57BL/6 mice^[2].
MOTS-c (human) (5 mg/kg; ip; twice daily; 4 days) acetate can reduce inflammation associated with obesity and insulin resistance by recruiting IL-6 and TNF-α in an acute treatment model in male CD-1 mice^[2].
MOTS-c (human) (50 mg/kg; ip; once a day; single dose) acetate can reduce paw licking time and inhibit the expression of spinal p-ERK/p-JNK/p-P38 and c-fos in the formalin inflammation model of male ICR mice, exerting anti-nociceptive and anti-inflammatory effects^[3].
MOTS-c (human) (0.5 mg/kg; ip; once a day; 8 weeks) acetate can reduce fasting blood glucose, glycosylated serum protein and blood lipid levels, improve myocardial ultrastructural damage and activate myocardial AMPK/Nrf2 antioxidant pathway^[4] in the male Sprague-Dawley rat type 2 diabetes model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (6-8-week-old) with controlled-cortical impact (CCI)-induced traumatic brain injury model^[2]
Dosage:	25 mg/kg, 50 mg/kg MOTS-c (human) (saline)
Administration:	Intraperitoneal injection, once daily, for 21 days starting 1 hour post-injury
Result:	At 50 mg/kg, MOTS-c reduced neurological severity scores (NSS) by 45% and improved rotarod performance (latency increased by 50%) compared to injured controls. Brain tissue analysis showed reduced HMGB1 expression (30% decrease), TLR4/NF-κB pathway inhibition, and lower pro-inflammatory cytokines (TNF-α, IL-6) in the ipsilateral cortex. OBB-NC formulation (3 mg/kg) showed comparable effects with enhanced BBB penetration.

Animal Model:	Male ICR mice (25-30 g, 6-week-old) with Formalin-induced paw inflammation model^[3]
Dosage:	50 mg/kg MOTS-c (human) (saline)
Administration:	Intraperitoneal injection, 1 hour before formalin challenge, single dose
Result:	Significantly reduced licking time in the late phase (phase II, 11-40 min) by 60% compared to vehicle controls. Immunohistochemistry revealed decreased c-fos positive cells (40% reduction) in the spinal dorsal horn, with Western blot confirming suppressed phosphorylation of ERK (Thr202/Tyr204), JNK (Thr183/Tyr185), and P38 (Thr180/Tyr182) by 30-50%. The AMPK inhibitor Compound C abolished these effects.

Animal Model:	Male Sprague-Dawley rats (220-240 g, 7-week-old) with high-fat diet/streptozotocin-induced type 2 diabetes model^[4]
Dosage:	0.5 mg/kg MOTS-c (human) (saline)
Administration:	Intraperitoneal injection, once daily, for 8 weeks
Result:	Significantly decreased fasting blood glucose (FBG) by 35%, HOMA-IR by 40%, and plasma triglycerides (TG)/total cholesterol (TC) by 25-30% compared to diabetic controls. Reduced mitochondrial swelling and cristae damage, with increased SOD/GSH activity and upregulated p-AMPK, Nrf2, and Keap1 protein expression in the heart. Combined with exercise, MOTS-c further enhanced glucose disposal and attenuated oxidative stress (MDA reduction by 50%).

Molecular Weight

2234.64

Formula

C₁₀₃H₁₅₆N₂₈O₂₄S₂

Appearance

Solid

Color

White to off-white

Sequence

Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg

Sequence Shortening

MRWQEMGYIFYPRKLR

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 6.25 mg/mL (2.80 mM; Need ultrasonic)

DMSO : 4 mg/mL (1.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.4475 mL	2.2375 mL	4.4750 mL
5 mM	---	---	---
10 mM	---	---	---

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 98.97%

Select Batch:

Data Sheet (278 KB) SDS (252 KB)

COA (242 KB) LCMS (97 KB) Elemental Analysis Report (101 KB)

Handling Instructions (2659 KB)

References

[1]. Mohtashami Z, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022 Oct 9;23(19):11991. [Content Brief]

[2]. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015 Mar 3;21(3):443-54. [Content Brief]

[3]. Yin X, et al. The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test. Eur J Pharmacol. 2020 Mar 5;870:172909. [Content Brief]

[4]. Tang M, et al. The role of MOTS-c-mediated antioxidant defense in aerobic exercise alleviating diabetic myocardial injury. Sci Rep. 2023 Nov 13;13(1):19781. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O

1 mM

0.4475 mL

2.2375 mL

4.4750 mL

11.1875 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.